An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
National Collaborating Centre for Cancer (UK).
London: National Institute for Health and Clinical Excellence (NICE); 2012 Sep. (NICE Clinical Guidelines, No. 151.)
Non-Hodgkin's Lymphoma: Diagnosis and Management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)
Addendum to Haematological Cancers: improving outcomes (update).
London: National Institute for Health and Care Excellence (NICE); 2016 May.
Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision.
Geneva: World Health Organization; 2010.
Brentuximab Vedotin (Adcetris): Indication: Brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in previously untreated high-risk Hodgkin lymphoma (HL) in the pediatric population. Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of previously untreated patients with advanced stage HL: CADTH Reimbursement Recommendation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Sep.
Non-Alcoholic Fatty Liver Disease: Assessment and Management.
National Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 49.)
Axicabtagene ciloleucel (Yescarta): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory grade 1, 2, or 3a follicular lymphoma after 2 or more lines of systemic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.
Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection [Internet].
Geneva: World Health Organization; 2018 Jul.
Coeliac Disease: Recognition, Assessment and Management.
London: National Institute for Health and Care Excellence (NICE); 2015 Sep. (NICE Guideline, No. 20.)
Nivolumab (Opdivo): CADTH Reimbursement Recommendation: Indication: As monotherapy, for the adjuvant treatment of adult patients with stage IIB or IIC melanoma following complete resection [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.
Axicabtagene Ciloleucel (Yescarta): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.
Polatuzumab Vedotin (Polivy): CADTH Reimbursement Recommendation: Indication: Large B-cell lymphoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan.
Ibrutinib (Imbruvica): CADTH Reimbursement Recommendation: Indication: Ibrutinib, with or without rituximab, for the treatment of adult patients with previously treated refractory or relapsed Waldenström’s macroglobulinemia [Internet].
Lisocabtagene Maraleucel (Breyanzi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.
Zanubrutinib (Brukinsa): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug.
Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults.
Geneva: World Health Organization; 2014.
Epcoritamab (Epkinly): CADTH Reimbursement Recommendation: Indication: Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma Grade 3B after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy [Internet].
Consolidated Strategic Information Guidelines for HIV in the Health Sector.
Geneva: World Health Organization; 2015 May.
CADTH Reimbursement Reviews and Recommendations.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on